Vitamin E / VEGF Cancer Research Results

VitE, Vitamin E: Click to Expand ⟱
Features:

Vitamin E (VitE) = fat-soluble antioxidant family (tocopherols: α-, β-, γ-, δ-; tocotrienols: α-, β-, γ-, δ-), from diet (vegetable oils, nuts/seeds) and supplements (commonly α-tocopherol).
Primary mechanisms (conceptual rank):
1) Lipid-peroxidation chain-breaking antioxidant → ↓ membrane oxidative damage / ↓ lipid-ROS (anti-ferroptotic bias).
2) Redox-signaling modulation (secondary): alters ROS-triggered stress pathways (NF-κB, MAPK), inflammation tone.
3) Gene-regulatory adaptation: shifts antioxidant/stress programs (incl. NRF2 axis; context can be protective in normal tissues yet pro-survival in tumors).
4) Isoform-dependent anti-cancer signaling (notably tocotrienols): apoptosis/anti-proliferation, membrane/ER stress effects (model-dependent).
PK / bioavailability: absorption is fat-dependent; circulating levels rise modestly vs many in-vitro study doses; isoforms differ (tocotrienols often have distinct kinetics vs αT).
In-vitro vs systemic exposure: many cell studies use ≥10–100 µM or high bolus conditions that commonly exceed achievable free plasma/tissue levels from typical oral dosing (esp. for non-α isoforms).
Clinical evidence status: cancer prevention data are mixed and isoform-specific; high-dose αT (e.g., 400 IU/d) showed harm in prostate cancer risk (SELECT). Evidence is not “anti-cancer RCT–proven” and is best framed as context-/isoform-dependent with meaningful clinical constraints.

It primarily comprises two families:
Tocopherols
  α-Tocopherol (most active and abundant form found in human tissues)
  β-Tocopherol
  γ-Tocopherol
  δ-Tocopherol
Tocotrienols
  α-Tocotrienol
  β-Tocotrienol
 γ-Tocotrienol
  δ-Tocotrienol


-Vitamin E can neutralize free radicals, which are reactive molecules that may damage cells and potentially contribute to cancer development. This antioxidant property has led researchers to explore whether vitamin E could help protect cells from damage during cancer treatment.
-Cancer Prevention: Some epidemiological studies suggested that higher intake of vitamin E (usually through diet rather than supplements) might be associated with a lower risk of certain cancers.

Vitamin E (VitE) — Cancer-Relevant Pathways (isoform- and context-dependent)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Lipid peroxidation / membrane protection ↓ (context-dependent) ↓ P Antioxidant “chain-breaker” in membranes Core pharmacology; can protect normal tissue but may also protect tumor cells from oxidative stress therapies (model-dependent).
2 ROS tone ↓ (context-/dose-dependent) ↓ P→R ↓ oxidative stress signaling Often secondary to lipid radical scavenging; can blunt ROS-mediated cytotoxicity from chemo/radiation in some settings (context-dependent).
3 Ferroptosis axis (iron/lipid-ROS death) ↓ (anti-ferroptotic bias) ↓ P→R Suppresses lipid-ROS propagation Mechanistically coherent: VitE tends to oppose ferroptotic lipid peroxidation; may be undesirable where ferroptosis is leveraged therapeutically.
4 NRF2 antioxidant program ↑ (context-dependent) ↑ G Adaptive antioxidant response NRF2 can be tissue-protective in normal cells yet pro-survival / resistance-promoting in some tumors (context-dependent).
5 NF-κB / inflammatory signaling ↓ (model-dependent) ↓ (often) R→G Anti-inflammatory bias Redox-linked; magnitude varies by isoform (αT vs γT vs tocotrienols) and stimulus.
6 Apoptosis / mitochondrial stress ↑ (tocotrienols & high concentration only) ↔ / ↓ (protective) R→G Pro-apoptotic signaling (select models) Tocotrienols are more often reported pro-apoptotic vs αT; frequently requires supra-physiologic exposure (model-dependent).
7 Ca²⁺ handling (ER/mitochondrial stress coupling) ↔ (model-dependent) ↔ R Stress-modulating cross-talk Not a universal “signature axis” for VitE, but can matter when ER stress/mitochondrial dysfunction is the readout.
8 Clinical Translation Constraint — — — Prevention/adjunct limitations Isoform + dose matter; high-dose αT (400 IU/d) increased prostate cancer risk in SELECT; in-vitro dosing often exceeds realistic systemic exposure.

TSF Legend: P: 0–30 min (direct redox/membrane effects)   |   R: 30 min–3 hr (acute stress signaling)   |   G: >3 hr (gene-regulatory adaptation)


Vitamin E (α-tocopherol) — Alzheimer’s Disease (AD) / Neuronal-Protection-Relevant Axes

Rank Pathway / Axis Cells (AD-relevant; mostly “normal” neurons/glia under stress) TSF Primary Effect Notes / Interpretation
1 Lipid peroxidation / membrane oxidative injury ↓ P Neuroprotective antioxidant (membrane) Mechanistic fit to oxidative-stress hypothesis; strongest “core” axis for VitE in CNS stress contexts.
2 ROS tone ↓ P→R ↓ oxidative stress signaling Often downstream of lipid radical scavenging; may reduce oxidative damage markers (model-dependent).
3 Neuroinflammation (NF-κB-linked) ↓ (model-dependent) R→G Anti-inflammatory bias Magnitude depends on model and background diet/status.
4 Clinical evidence constraint — — Mixed RCT outcomes by stage MCI: 2000 IU/d VitE did not significantly delay progression to AD in a 3-year trial; mild–moderate AD: 2000 IU/d αT slowed functional decline vs placebo in TEAM-AD; earlier ADCS trial also reported slowed progression signals (stage-dependent).

TSF Legend: P: 0–30 min   |   R: 30 min–3 hr   |   G: >3 hr
VEGF, Vascular endothelial growth factor: Click to Expand ⟱
Source: HalifaxProj (inhibit)
Type:
A signal protein produced by many cells that stimulates the formation of blood vessels. Vascular endothelial growth factor (VEGF) is a signal protein that plays a crucial role in angiogenesis, the process by which new blood vessels form from existing ones. This process is vital for normal physiological functions, such as wound healing and the menstrual cycle, but it is also a key factor in the growth and spread of tumors in cancer.
Because of its significant role in tumor growth and progression, VEGF has become a target for cancer therapies. Anti-VEGF therapies, such as monoclonal antibodies (e.g., bevacizumab) and small molecule inhibitors, aim to inhibit the action of VEGF, thereby reducing blood supply to tumors and limiting their growth. These therapies have been used in various types of cancer, including colorectal, lung, and breast cancer.
Scientific Papers found: Click to Expand⟱
4764- CoQ10,  VitE,    Auxiliary effect of trolox on coenzyme Q10 restricts angiogenesis and proliferation of retinoblastoma cells via the ERK/Akt pathway
- in-vitro, RPE, Y79 - in-vitro, Nor, ARPE-19 - in-vivo, NA, NA
tumCV↓, Apoptosis↑, ROS↑, MMP↓, TumCCA↑, VEGF↓, ERK↓, Akt↓, ChemoSen↑, chemoP↑, toxicity↓, angioG↓,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Cell Cycle & Senescence ⓘ

TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

ERK↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGF↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,  

Functional Outcomes ⓘ

chemoP↑, 1,   toxicity↓, 1,  
Total Targets: 12

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: VEGF, Vascular endothelial growth factor
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:307  Target#:334  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page